Stefan Krauss


Affiliation: Institute for Cancer Research
Country: Norway


  1. Solberg N, Melheim M, Strand M, Olsen P, Krauss S. MEK Inhibition Induces Canonical WNT Signaling through YAP in KRAS Mutated HCT-15 Cells, and a Cancer Preventive FOXO3/FOXM1 Ratio in Combination with TNKS Inhibition. Cancers (Basel). 2019;11: pubmed publisher
    ..RNA sequencing analysis suggests that combined TNKS/MEK inhibition induces metabolic stress responses in HCT-15 cells promoting a positive FOXO3/FOXM1 ratio to reduce antioxidative and cryoprotective systems. ..
  2. Haikarainen T, Krauss S, Lehtiƶ L. Tankyrases: structure, function and therapeutic implications in cancer. Curr Pharm Des. 2014;20:6472-88 pubmed
    ..The recent, highly potent and selective inhibitors possess several properties of lead compounds and can be used for proof-of-concept studies in cancer and other Tankyrase linked diseases. ..
  3. Haikarainen T, Waaler J, Ignatev A, Nkizinkiko Y, Venkannagari H, Obaji E, et al. Development and structural analysis of adenosine site binding tankyrase inhibitors. Bioorg Med Chem Lett. 2016;26:328-333 pubmed publisher
    ..The structural analysis allows further rational development of this compound class as a potent and selective tankyrase inhibitor. ..
  4. Machon O, Masek J, Machonova O, Krauss S, Kozmik Z. Meis2 is essential for cranial and cardiac neural crest development. BMC Dev Biol. 2015;15:40 pubmed publisher
    ..Meis2-null mice are embryonic lethal. Our results reveal a critical role of Meis2 during cranial and cardiac neural crest cells development in mouse. ..